Anal cancer

3 trials MedDRA PT
3 Registered trials
0 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody 1 substance
Unknown / small molecule 1 substance
Phase I/II: 1 Phase I: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase I/II

1 trial
  • Transgene Commercial
    AVELUMAB; TIPAPKINOGENE SOVACIVEC
    2024-515119-23-00 2 countries 2017 n=142
    Ended

Phase I

2 trials
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502381-25-01 4 countries 2024 n=97
    Ended
  • Nykode Therapeutics ASA Commercial
    IMP not specified
    2023-509996-18-00 2 countries 2022 n=40
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 1 Phase I 0
Nykode Therapeutics ASA Commercial 1 Phase I 0
Transgene Commercial 1 Phase I/II 0
New trials by year
2022
1
2024
1
← All indication landscapes